New developments in the treatment of metastatic gastric cancer: focus on trastuzumab

Abstract

Patients with metastatic gastric cancer have a poor outcome. The development of new combinations of chemotherapy has led to steady but only modest gains in overall survival with largest effects reported with two- and three-drug regimens. Trastuzumab, a fully humanized monoclonal antibody directed at the human epidermal growth factor receptor-2 (HER2), has been found to improve response rate and survival in patients with advanced gastric cancer. This update will review the role of HER2 and summarize therapeutic advances in the use of trastuzumab in advanced gastric cancer.

Keywords:

• gastric
• gastroesophageal
• adenocarcinoma
• chemotherapy
• trastuzumab

Disclosure

Jeffrey S Rose: None. Tanios S Bekaii-Saab: Consulting fees and grant support from Genentech.